Genetic Technologies Limited · ASX:GTG

Genetic Technologies — 2010 Australian Life Science Summit

5 slides from Genetic Technologies's conference presentation, Oct 18, 2010

  1. Slide 1: ASX Announcement: Presentation

    For personal use only ASX ANNOUNCEMENT October 18th, 2010 ___________________________________________________________________________________ Presentation Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to release a copy of the presentation that will be made by Dr. Paul MacLeman, Ch

  2. Slide 2: Highlights and Snapshot

    10/18/2010 GENETIC TECHNOLOGIES LIMITED For personal use only Highlights $10m revenue 2009/10 with tapering burn rate Cancer diagnostics and genetic testing focus  Revenue generating IP estate High growth prospects through launch first in class sporadic breast cancer risk test globally Dr Paul M

  3. Slide 3: Cancer Management Portfolio Strategy

    10/18/2010 Cancer Management Portfolio Strategy For personal use only 2005 launch Nov ’09 launch Planned H2 2010 launch Feb ’10 10 launch May ’10 launch - Unique portfolio approach: global deployment in‐house tests ‐ Assembling best in class cancer management tools for PacRim deployment: further pro

  4. Slide 4: BREVAGen – first validated test for non-familial breast cancer risk

    10/18/2010 BREVAGen™ – first validated test for non‐familial breast cancer risk For personal use only Gail Score  1.6m breast biopsy patients pa (USA)  1m patients with indeterminate outcomes  BREVAGen re‐classifies ~25% of these enabling preventive SERM therapy  SERMs effective at preventing 6

  5. Slide 5: Oncology Focus and Financials

    10/18/2010 Oncology Focus  New technologies driving For personal use only targeted interventions & extending lives  Molecular diagnosis of cancer is most attractive segment of the Dx industry  Focused market & efficient sales process  Strong accelerating growth forecast next 4 years  Historical

Genetic Technologies — 2010 Australian Life Science Summit on 6ix